Under the deal, Novo will receive exclusive global rights to develop and commercialize so-called non-incretin oral therapies, which belong to a different class of medicines than its popular weight-loss and diabetes drugs Wegovy and Ozempic. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/novo-nordisk-partners-with-deep-apple-in-812-million-weight-loss-drug-license-deal/121790411